Gene Expression and the Lymphoma Research Consortium

Multidisciplinary Approach to Care

The Lymphoma Research Consortium combines excellent patient care with research and is dedicated to finding a cure for the both Hodgkin and non-Hodgkin lymphomas.

Established a comprehensive multidisciplinary clinical treatment team with expertise in combined modality treatments, high-dose treatments with bone marrow/stem cell transplant, monoclonal antibody treatment (including radioimmunotherapy), and investigational new therapies for recurrent/resistant disease.

Lymphoma Medical Oncology

The Medical Oncology section of the Lymphoma Research Consortium offers:

  • Combined modality treatments, high-dose treatments with bone marrow/stem cell transplants and monoclonal antibody treatment
  • Investigational new therapies for recurrent/resistant disease
  • Clinical trials that bring the most active new agents to our patients.
  • Laboratory research on lymphoma biology
  • The exploration of new strategies to prevent, diagnose and cure lymphomas
Additional Related Links:

Through a collaboration with Nanostring and a patent license from TLA

The UA gene expression profiling technology is being used to guide the clinical development of Celgene’s Revlamid.

Spotlight Type: